Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025OncoImmunologyOpen Access

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJoao GorgulhoTTTimo TrenknerEKEva Kinkel

Discussion

Loading...

Member takes

Overview

Analysis of soluble and membrane-bound immune checkpoints reveals their potential as biomarkers for lymphoma outcomes.

Key Points

  • High levels of soluble immune checkpoints in lymphoma patients are linked to worse disease control and survival.
  • The combined score of three soluble immune checkpoints outperforms standard prognostic methods like NCCN-IPI.
  • Membrane-bound markers in peripheral blood mononuclear cells provide additional prognostic value.
  • Prospective validation of the 2COMPIC-Score could improve therapy decision-making in lymphoma patients.

Cite This Study

Gorgulho et al. (2025) studied this question.

synapsesocial.com/papers/68bb3efd2b87ece8dc957e8dhttps://doi.org/10.1080/2162402x.2025.2543511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study2024
  2. 2Peripheral immune checkpoints predict prognosis and reveal PD-1/treg/IL-10 crosstalk in B cell lymphoma2025
  3. 3Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies2024 · 12 citations
  4. 4Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L12026
  5. 558P Soluble immune checkpoints as a promising avenue for breast cancer stratified by molecular subtype2024